Shots:Shots:

• The company will conduct its third study in collaboration with ADH at River Oaks Hospital and Clinics to determine the role of its HB-adMSCs in decreasing the severity of illness in patients with COVID-19
• The P-II study will assess HB-adMSCs vs PBO in patients receiving hydroxychloroquine and azithromycin and not receiving this combination therapy. Those receiving treatment will receive 4 doses of 100M HB-adMSCs over 10days
• The goal of the collaboration is to provide HB-adMSCs to the patients which helps the patient’s immune system to resist the damage associated with COVID-19. The company’s first and second FDA approvals for COVID-19 are focused on prevention while the third trial is for treatment of hospitalized patients

Click here ­to­ read full press release/ article | Ref: Hope Biosciences | Image: Hope Biosciences